Home Latest Articles
Latest Articles
  • Chengzheng LIU, Xingchen WEI, Gang FANG, Yu HU, Jinxi DING
    World Clinical Drug. 2025, 46(6): 612-620.
    Objective

    To systematically evaluate the efficacy and safety of ustekinumab compared with other second-line drugs for Crohn's disease(CD).

    Methods

    A systematic search of PubMed, Embase, Cochrane Library, and other databases for cohort studies comparing ustekinumab with other second-line therapies for the treatment of CD. Meta-analysis was performed by Review Manager 5.4 software.

    Results

    A total of 10 literature studies were included, 1 222 patients in ustekinumab group and 949 patients in other drug groups. The results showed that the clinical remission rate[OR=1.75, 95%CI: (1.38, 2.21), P<0.001], steroid-free clinical remission rate[OR=1.54, 95%CI: (1.17, 2.01),P=0.002] and clinical response rate[OR=2.69, 95%CI: (1.10, 6.58), P=0.030] in ustekinumab group were higher than those of the other drug groups. In addition, the incidence of adverse events[OR=0.29, 95%CI: (0.09, 0.96), P=0.040]and discontinuation rate[OR=0.28, 95%CI: (0.17, 0.46), P<0.001] in ustekinumab group were lower than those of the other drug groups.

    Conclusion

    Ustekinumab is more effective and safer than the other second-line drugs for CD.

  • Biwen TANG, Huijuan CHAO, Yueliang HU, Junli ZUO, Qian WANG
    World Clinical Drug. 2025, 46(6): 621-628.
    Objective

    To investigate the risk factors related to arterial stiffness in patients with obstructive sleep apnea(OSA) combined with non-dipper hypertension.

    Methods

    A total of 264 patients with hypertension admitted to the geriatrics department of Ruijin hospital, from July 2018 to December 2022 were enrolled. General clinical data and biochemical indicators were collected, and sleep opnea monitoring, 24-hour ambulatory blood pressure monitoring,and carotid-femoral pulse wave velocity(c-fPWV) measurements were performed. Patients were grouped based on ambulatory blood pressure and apnea-hypopnea index(AHI) to study the risk factors for arterial stiffness in patients with OSA combined with non-dipper hypertension.

    Result

    A total of 264 patients with OSA combined with hypertension were included, with an average age of(49.88±12.48) years, of which 195 patients had OSA combined with non-dipper hypertension, accounting for 73.86%. Patients with moderate to severe OSA combined with non-dipper hypertension were older[(52.33±12.78) years vs. (45.88±11.34) years, P<0.001] and had a faster c-fPWV[(10.19±3.76) m/s vs.(7.76±1.55) m/s, P<0.001]. The office pulse pressure in patients with moderate to severe OSA combined with non-dipper hypertension was significantly higher than that in patients with mild OSA combined with non-dipper hypertension[(57.00±20.00) mmHg vs. (51.00±11.00) mmHg, P=0.031]. The c-fPWV in patients with OSA combined with non-dipper hypertension was positively correlated with the AHI, 24-hour systolic blood pressure, and office systolic blood pressure. Logistic regression analysis showed that AHI[odds ratio(OR)=1.03, 95% confidence interval(CI):1.01—1.06, P<0.05], age(OR=1.14, 95%CI: 1.06—1.12, P<0.05), and office diastolic blood pressure(OR=1.08,95%CI: 1.01—1.16, P<0.05) were independent risk factors for increased c-fPWV.

    Conclusion

    Patients with moderate to severe OSA combined with non-dipper hypertension exhibit significantly elevated c-fPWV, which is closely associated with the severity of OSA and blood pressure levels. AHI, age, and office diastolic blood pressure are independent risk factors for increased c-fPWV. Therefore, patients with OSA combined with non-dipper hypertension, particularly those with moderate to severe OSA, should focus on early screening and intervention for arterial stiffness to reduce the risk of cardiovascular events.

  • Yujia ZHU, Xuejie WANG, Ziqiu WANG, Wen DU, Zhenhua YANG, Chenni GAO
    World Clinical Drug. 2025, 46(6): 629-631.
  • Jing GAO, Yang ZHUO, Xin ZHU
    World Clinical Drug. 2025, 46(6): 632-636.
  • Lihong CHEN, Yan QIANG
    World Clinical Drug. 2025, 46(5): 429-433.

    Psoriasis is a chronic, recurrent, immune-mediated systemic inflammatory skin disease that significantly impairs patients' physical and mental health as well as the quality of life of patients. With the widespread application of treatment methods such as biological agents, the therapeutic effect of psoriasis has significantly improved, but the problem of recurrence remains prominent. Immune abnormalities (such as tissue resident memory T cells, cytotoxic T cell 17), genetic susceptibility, infectious factors, environmental changes, and unhealthy lifestyles are important triggers for psoriasis recurrence. Meanwhile, there are differences in the recurrence time of different types of biologics after discontinuation, and the risk of recurrence is closely related to patient's compliance and comorbidity status. The article systematically reviewed the relevant mechanisms, influencing factors, and intervention strategies for psoriasis vulgaris recurrence, and proposed multidimensional prevention and intervention strategies for recurrence issues, including optimizing biological agent management, combination therapy regimens, improving lifestyle, and long-term follow-up mechanisms, providing reference for clinical treatment.

  • Wei LU, Yan QIANG, Congying LI
    World Clinical Drug. 2025, 46(5): 434-438.

    Vitiligo is a common acquired skin mucosal pigment loss disease, and there is no cure. The pathogenesis of vitiligo is complex, involving multiple factors such as genetics, autoimmunity, and oxidative stress. With the deepening research on the pathogenesis of vitiligo, biologics targeting specific sites have been continuously developed, especially targeted treatments for immune regulation and anti-inflammatory response, which provide new ideas for the treatment of vitiligo. This article focused on the feasibility of using biologics as a new treatment method for vitiligo, in order to provide reference for exploring better treatment options.

  • Zhuo ZHANG, Cheng QIN, Fang WANG, Xuesong YANG, Jianzhou YE
    World Clinical Drug. 2025, 46(5): 439-445.

    Atopic dermatitis (AD) is a common chronic inflammatory skin disease that seriously affects the quality of life of patients. Traditional treatments such as topical steroids and immunosuppressants have limited efficacy in some patients and are accompanied by adverse reactions. In recent years, biologics have provided new treatment options for patients with moderate to severe AD by targeting key inflammatory factors. Dupilumab, as the first approved biologic, significantly improved patients' skin symptoms and pruritus. Subsequently, drugs such as tralokinumab, lebrikizumab, and nemolizumab further expanded the options for targeted therapy. Biologics have shown promising prospects in improving the treatment outcomes of patients with moderate to severe AD, and are expected to further improve efficacy and affordability through personalized medicine, optimized dosing strategies, and cost control. This article reviewed the targets, mechanisms of action, and clinical research progress of major biological agents, in order to provide reference for the clinical treatment of AD patients.

  • Chunling DING, Hongjun GU, Haiyan ZHU, Baoping FANG
    World Clinical Drug. 2025, 46(5): 446-450.
    Objective

    To explore the influence of ciprofol on anesthetic effect and vital signs of patients undergoing hysteroscopy.

    Methods

    A total of 114 patients who underwent hysteroscopic surgery under general anesthesia from January 2023 to October 2024 were selected and randomly divided into a control group and a study group, with 57 cases in each group. The control group received anesthesia induction and maintenance with propofol injection, while the study group received ciprofol injection. The vital signs, disappearance time of eyelash reflex, wake up time, orientation recovery time and occurrence of adverse reactions were compared between the two groups.

    Results

    Before anesthesia, there was no statistically significant difference in heart rate (HR), peripherals oxygen saturation (SpO2), and mean arterial pressure (MAP) between the two groups (P>0.05). After anesthesia induction and at recovery, the MAP, SpO2 and HR in both groups decreased first and then increased, and the MAP and SpO2 in the study group were higher than those in the control group (P<0.05), and the wake up time of the study group was longer than that of the control group (P<0.05).There was no statistically significant difference in the disappearance time of eyelash reflex and the orientation recovery time between the two groups (P>0.05). The incidence of adverse reactions in the study group was lower than that in the control group (3.51% vs. 14.04%, P<0.05).

    Conclusion

    Ciprofol has a good anesthetic effect on patients undergoing hysteroscopic surgery. It can effectively maintain the stability of vital signs during and after the operation, and the incidence of adverse reactions is low.

  • Xinyue XING, Jingyi CHEN, Xiaoying SONG, Jiajie XIE, Danfei LOU
    World Clinical Drug. 2025, 46(5): 457-464.
    Objective

    To observe the clinical efficacy of Bushen Huoxue decoction in treating carotid atherosclerosis (CAS) with kidney deficiency and blood stasis, and its influence on blood lipid, inflammation, complement activation and carotid ultrasound.

    Methods

    A total of 90 CAS patients with kidney deficiency and blood stasis who visited our hospital were included and randomly divided into control group and experimental group, 45 cases in each group.The control group was treated with conventional Western medicine, and the experimental group was treated with Bushen Huoxue decoction on the basis of the control group. The course of treatment was 12 weeks. The therapeutic efficacy, the traditional Chinese medicine (TCM) syndrome scores, lipid levels, carotid intima-media thickness, pulse wave conduction velocity, maximum plaque area, safety indicators (blood routine, electrocardiogram, liver and kidney function) of the two groups were recorded and compared before and after treatment. The serum levels of ficolin (FCN)3, MBL-associated serine protease (MASP)-1, tumor necrosis factor (TNF)-α, interleukin (IL)-6, complement C3 and C4 were detected by enzyme-linked immunosorbent assay.

    Results

    The total effective rate of the experimental group was higher than that of the control group (82.05% vs. 52.78%,P<0.05). After treatment, compared with the control group, the levels of total cholesterol, low density lipoprotein cholesterol, FCN3, MASP-1, complement C4, TNF-α in the experimental group were decreased (P<0.05), TCM syndrome scores and high density lipoprotein cholesterol level were increased (P<0.05), and pulse wave conduction velocity was decreased (P<0.05). During treatment, no significant adverse reactions or adverse events occurred in both groups.

    Conclusion

    Bushen Huoxue decoction can effectively improve the clinical symptoms of patients with CAS, improve the levels of blood lipids, inflammation and carotid ultrasound indexes, and the mechanism may be related to complement activation.

  • Yun YANG, Na ZHAO, Yan XU, Yang ZHAO
    World Clinical Drug. 2025, 46(5): 465-470.
    Objective

    To evaluate the budget impact of the combination therapy of nivolumab and ipilimumab for the treatment of unresectable malignant pleural mesothelioma after its inclusion in the China's National Reimbuirsement Drug List (NRDL).

    Methods

    This study constructed a 5-year (2024—2028) budget impact analysis model from the perspective of the Chinese government health insurance authority to simulate the budget changes after the combination therapy of nivolumab and ipilimumab was included in the NRDL. The model analyzed factors such as the target population, drug market share, and treatment costs, comparing healthcare expenditures in scenarios with and without insurance coverage.One-way sensitivity analysis was performed to assess model robustness.

    Results

    After inclusion in the NRDL, the incremental expenditure from 2024 to 2028 mainly stems from health insurance payment portion of drug costs, with a cumulative increase of 66.645 million yuan. However, the overall financial impact on the insurance fund remains minimal.Sensitivity analysis showed that drug prices, reimbursement rates, and insurance coverage rates were the key factors affecting budget changes.

    Conclusion

    Although the combination therapy of nivolumab and ipilimumab included in the NRDL will increase expenditure, the impact on the overall fund burden is limited.

News